• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体对尿激酶型纤溶酶原激活剂的抑制作用:对人肿瘤在裸鼠体内扩散的影响。

Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.

作者信息

Ossowski L, Russo-Payne H, Wilson E L

机构信息

Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021.

出版信息

Cancer Res. 1991 Jan 1;51(1):274-81.

PMID:1988089
Abstract

Nude mice given inoculations s.c. of a human squamous carcinoma--HEp3 (1.5 x 10(6) cells/mouse)--developed invasive tumors that produced high levels of urokinase-type plasminogen activator (uPA) and metastasized predictably to the lungs and lymph nodes of the host. To investigate the role of uPA in invasion and metastasis, mice given inoculations of tumor cells were treated daily with s.c. injections of specific, anti-human uPA antibodies (rabbit polyclonal, 150 inhibitory units; mouse monoclonal, 3000 inhibitory units/mouse/day). Control mice received either saline or preimmune rabbit immunoglobulins. A total of approximately 50 mice was studied. The tumors were surgically excised 10 to 17 days postinoculation when weighing 1 to 2 g. Antibody administration was discontinued after tumor excision. Two strategies were used: (a) following the removal of tumors the mice were maintained and observed until respiratory distress, indicative of lung metastasis, was evident; or (b) their lungs were examined for evidence of metastasis on the day of tumor removal. While histological sections of s.c. tumors excised from control mice indicated extensive local invasion, evidence of invasion was absent in most tumors excised from mice in which tumor uPA was inhibited by the antibody (P less than 0.025). The inhibition of local invasion did not, however, lead to a reduced incidence of distant metastasis. Since we found that the presence of HEp3 tumors in mice elicits a pronounced granulocytosis, we propose that this response may facilitate the spread of tumor cells by a mechanism independent of endogenous tumor proteases.

摘要

给裸鼠皮下接种人鳞状细胞癌HEp3(1.5×10⁶个细胞/只小鼠)后,它们长出了侵袭性肿瘤,这些肿瘤产生高水平的尿激酶型纤溶酶原激活剂(uPA),并可预测地转移至宿主的肺和淋巴结。为了研究uPA在侵袭和转移中的作用,给接种肿瘤细胞的小鼠每天皮下注射特异性抗人uPA抗体(兔多克隆抗体,150个抑制单位;鼠单克隆抗体,3000个抑制单位/只小鼠/天)进行治疗。对照小鼠接受生理盐水或免疫前兔免疫球蛋白。共研究了约50只小鼠。接种后10至17天,当肿瘤重量达到1至2克时,将肿瘤手术切除。肿瘤切除后停止抗体给药。采用了两种策略:(a) 切除肿瘤后,维持并观察小鼠,直到出现呼吸窘迫(表明发生肺转移);或(b) 在切除肿瘤当天检查其肺部有无转移迹象。虽然从对照小鼠切除的皮下肿瘤组织切片显示有广泛的局部侵袭,但在从抗体抑制肿瘤uPA的小鼠切除的大多数肿瘤中,没有侵袭迹象(P<0.025)。然而,局部侵袭的抑制并未导致远处转移发生率降低。由于我们发现小鼠体内HEp3肿瘤的存在会引发明显的粒细胞增多,我们提出这种反应可能通过一种独立于内源性肿瘤蛋白酶的机制促进肿瘤细胞的扩散。

相似文献

1
Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.抗体对尿激酶型纤溶酶原激活剂的抑制作用:对人肿瘤在裸鼠体内扩散的影响。
Cancer Res. 1991 Jan 1;51(1):274-81.
2
Growth of a human carcinoma (HEp3) in nude mice: rapid and efficient metastasis.人癌(HEp3)在裸鼠体内的生长:快速且高效的转移。
J Cell Physiol. 1987 Nov;133(2):288-96. doi: 10.1002/jcp.1041330212.
3
Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.在实验性和自发性转移模型中,抗尿激酶型纤溶酶原激活剂抗体对Lewis肺癌转移的抑制作用。
Thromb Haemost. 1994 Apr;71(4):474-80.
4
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.靶向人胰腺癌细胞中的尿激酶型纤溶酶原激活物受体可抑制c-Met和胰岛素样生长因子-I受体介导的迁移、侵袭以及小鼠原位肿瘤生长。
Cancer Res. 2005 Sep 1;65(17):7775-81. doi: 10.1158/0008-5472.CAN-05-0946.
5
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.纤溶酶原激活物抑制剂-1抗体可抑制无胸腺小鼠体内人纤维肉瘤的肺转移。
Gen Diagn Pathol. 1995 May;141(1):41-8.
6
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.同基因乳腺癌模型中尿激酶的蛋白酶活性与肿瘤进展
J Natl Cancer Inst. 2006 Jun 7;98(11):756-64. doi: 10.1093/jnci/djj208.
7
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.在同基因肿瘤模型中,内在的粘着斑激酶活性通过调节尿激酶型纤溶酶原激活剂的表达来控制原位乳腺癌转移。
Oncogene. 2006 Jul 27;25(32):4429-40. doi: 10.1038/sj.onc.1209482. Epub 2006 Mar 20.
8
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).可溶性尿激酶型纤溶酶原激活物受体(CD87)过表达可减少乳腺癌肿瘤生长及肺转移。
Cancer Gene Ther. 2000 Feb;7(2):292-9. doi: 10.1038/sj.cgt.7700144.
9
Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.在尿激酶型纤溶酶原激活剂(uPA)缺陷型和野生型小鼠中诱导原发性皮肤黑素细胞肿瘤:细胞性蓝痣在uPA缺陷型动物中侵袭但不会进展为恶性黑色素瘤。
Cancer Res. 1996 Aug 1;56(15):3597-604.
10
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.前列腺癌DU145细胞表面介导了乳腺丝抑蛋白对尿激酶型纤溶酶原激活剂的抑制作用。
Cancer Res. 2000 Sep 1;60(17):4771-8.

引用本文的文献

1
Urokinase Plasminogen Activation System Modulation in Transformed Cell Lines.转化细胞系中尿激酶纤溶酶原激活系统的调节
Int J Mol Sci. 2025 Jan 15;26(2):675. doi: 10.3390/ijms26020675.
2
Ligand-Based Design of Selective Peptidomimetic uPA and TMPRSS2 Inhibitors with Arg Bioisosteres.基于配体的选择性肽模拟 uPA 和 TMPRSS2 抑制剂的 Arg 生物等排体设计。
Int J Mol Sci. 2024 Jan 23;25(3):1375. doi: 10.3390/ijms25031375.
3
Functional Validation of the Putative Oncogenic Activity of ..的假定致癌活性的功能验证
Biomedicines. 2022 Dec 30;11(1):102. doi: 10.3390/biomedicines11010102.
4
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).胰腺导管腺癌中的转移表型和免疫抑制肿瘤微环境:尿激酶型纤溶酶原激活物(PLAU)的关键作用。
Front Immunol. 2022 Dec 14;13:1060957. doi: 10.3389/fimmu.2022.1060957. eCollection 2022.
5
MacroH2A impedes metastatic growth by enforcing a discrete dormancy program in disseminated cancer cells.巨组蛋白 H2A 可通过在播散性癌细胞中强制实施一种离散的休眠程序来阻碍转移生长。
Sci Adv. 2022 Dec 2;8(48):eabo0876. doi: 10.1126/sciadv.abo0876.
6
Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA.通过与不同形式的 uPA 结合,DNA 适体对人尿激酶型纤溶酶原激活剂(uPA)酶活性和受体结合的抑制作用及其作为潜在治疗药物的研究
Int J Mol Sci. 2022 Apr 28;23(9):4890. doi: 10.3390/ijms23094890.
7
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.尿激酶型纤溶酶原激活剂(uPA)及其受体(uPAR)的多方面作用:诊断、预后及治疗应用
Front Oncol. 2018 Feb 12;8:24. doi: 10.3389/fonc.2018.00024. eCollection 2018.
8
The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues.纤溶酶原激活物抑制剂-1(PAI-1)上与低密度脂蛋白受体相关蛋白(LRP1)结合的高亲和力位点由四个碱性残基组成。
J Biol Chem. 2016 Jan 8;291(2):800-12. doi: 10.1074/jbc.M115.688820. Epub 2015 Nov 10.
9
Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth.使用小干扰发夹RNA(siRNA)下调尿激酶型纤溶酶原激活物(uPA)、尿激酶型纤溶酶原激活物受体(uPAR)和基质金属蛋白酶-9(MMP-9)可抑制胶质瘤细胞的侵袭、血管生成和肿瘤生长。
Neuron Glia Biol. 2004 May;1(2):165-76. doi: 10.1017/s1740925x04000237.
10
RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.RNA干扰介导的人脑膜瘤细胞中尿激酶型纤溶酶原激活剂及其受体的下调抑制肿瘤侵袭和生长。
Int J Oncol. 2006 Jun;28(6):1353-60.